ICON Public (NASDAQ:ICLR) Updates FY25 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $13.00-15.00 for the period, compared to the consensus EPS estimate of $14.86. The company issued revenue guidance of $8.05-8.65 billion, compared to the consensus revenue estimate of $8.50 billion. ICON Public also updated its FY 2024 guidance to 13.900-14.100 EPS.

ICON Public Stock Performance

ICON Public stock opened at $200.24 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. ICON Public has a 12 month low of $183.38 and a 12 month high of $347.72. The company has a market cap of $16.52 billion, a price-to-earnings ratio of 22.32, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20. The stock’s 50-day moving average is $211.31 and its 200-day moving average is $270.81.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The business had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the previous year, the business posted $3.10 EPS. The company’s quarterly revenue was down 1.2% on a year-over-year basis. Equities analysts anticipate that ICON Public will post 13.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ICLR shares. Baird R W downgraded ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. The Goldman Sachs Group lowered their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Leerink Partnrs raised ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Barclays lowered their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, Robert W. Baird cut their price objective on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $287.00.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.